Loading...
Despite the intuitive appeal of structured treatment interruption (STI), the strategy failed miserably in 2006, with several large trials yielding negative results. Most notable were the SMART (Strategies for Management of Antiretroviral Therapy) study and the Trivacan ANRS 1269 study, both of which used a CD4 count <250 cells/mm3 as the threshold for restarting therapy. Enrollment in the SMART study was halted when clinical progression was noted to be significantly more common with STI than with continuous therapy. The causes of morbidity and mortality were widely dispersed but included many conditions not traditionally thought of as AIDS-related (e.g., renal, hepatic, and cardiac disease) (ACC Nov 29 2006). Similar findings were reported …